Kairos Pharma, LTD.
SEC CIK 1962011 · KAPA · last insider filing 2025-12-30
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Bae Hyun W. | Director | filed 2024 - 2025 |
| Singhvi Rahul | Director | filed 2025 - 2025 |
| Yu John S | Director · CEO and Chairman | filed 2024 - 2025 |
| Keyoung Hansoo Michael | Director | filed 2024 - 2025 |
| Mazanet Rosemary | Director | filed 2024 - 2024 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Bhowmick Neil | Chief Scientific Officer | filed 2024 - 2025 |
| Murali Ramachandran | VP of Research and Development | filed 2024 - 2025 |
| Samuelson Doug | Chief Financial Officer | filed 2024 - 2025 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.